Filing Details

Accession Number:
0001615774-16-008485
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-11-18 19:44:08
Reporting Period:
2016-11-16
Filing Date:
2016-11-18
Accepted Time:
2016-11-18 19:44:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1557746 Aclaris Therapeutics Inc. ACRS () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1509160 Vivo Ventures Fund Vii, L.p. C/O Vivo Capital 575 High Street
Suite 201
Palo Alto CA 94301
No No Yes No
1538309 Vivo Ventures Vii Affiliates Fund, L.p. C/O Vivo Capital 575 High Street
Suite 201
Palo Alto CA 94301
No No Yes No
1565020 Vivo Ventures Vii, Llc C/O Vivo Capital 575 High Street
Suite 201
Palo Alto CA 94301
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-11-16 448,063 $23.25 3,653,934 No 4 S Indirect By Vivo Ventures Fund VII, L.P.
Common Stock Disposition 2016-11-16 9,765 $27.30 79,635 No 4 S Indirect By Vivo Ventures VII Affiliates Fund, L.P.
Common Stock Disposition 2016-11-18 440,402 $22.72 3,213,532 No 4 S Indirect By Vivo Ventures Fund VII, L.P.
Common Stock Disposition 2016-11-18 9,598 $22.72 70,037 No 4 S Indirect By Vivo Ventures VII Affiliates Fund, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Vivo Ventures Fund VII, L.P.
No 4 S Indirect By Vivo Ventures VII Affiliates Fund, L.P.
No 4 S Indirect By Vivo Ventures Fund VII, L.P.
No 4 S Indirect By Vivo Ventures VII Affiliates Fund, L.P.
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $24.90, inclusive. The reporting person undertakes to provide to Aclaris Therapeutics, Inc., any security holder of Aclaris Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
  2. Vivo Ventures VII, LLC ("VV LLC") is the general partner of Vivo Ventures Fund VII, L.P. ("VVF"), the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. In addition, each of Albert Cha, a director of the issuer, Frank Kung and Edgar Engleman is a managing member of VV LLC and may be deemed to share voting and dispositive power over the securities held by VVF. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
  3. VV LLC is the general partner of Vivo Ventures VII Affiliates Fund, L.P. ("VVAF"), the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. In addition, each of Albert Cha, a director of the issuer, Frank Kung and Edgar Engleman is a managing member of VV LLC and may be deemed to share voting and dispositive power over the securities held by VVAF. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.